What are ADC's

Our services

ADC Review
is made possible by:


Study Title
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma. (NCT01393717)

Trial Description
This phase II trial studies how well brentuximab vedotin (also known as SGN-035) before autologous (taken from an individual’s own cells) stem cell transplant works in treating patients with Hodgkin lymphoma (HL).

Monoclonal antibody-drug conjugates or ADCs such as brentuximab vedotin can block cancer growth in different ways by targeting certain cells.

This trial is sponsored by City of Hope Medical Center. [1]

Study Data

  • Condition: Hodgkin Lymphoma
  • Interventions:
    • Drugs used in this trial
      • brentuximab vedotin
      • Other: laboratory biomarker analysis
      • Genetic: protein expression analysis
  • Phase: II
  • Estimated Enrollment: 57
  • Start: October 2011
  • Estimated Completion: September 2016 (Final data collection date for primary outcome measure)
  • Last verified: June 2015

Study Schemata 

Screen Shot 2016-07-06 at 4.31.34 PM

Last Editorial review: July 7, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar